Ketamine
Small molecule targets TNF via inhibition
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | KETALAR | — | 1982-06-11 | fda.gov ↗ |
| Approved | US (FDA) | KETALAR | — | 1970-02-19 | fda.gov ↗ |
Trials 787 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 043 trials | ||||||
| Phase 0 | NCT06378528 | Sep 2026 → Sep 2027 | post-traumatic stress disorder | University of Wisconsin, Madison | Suspended | No outcome recorded |
| Phase 0 | NCT07211399 | Jul 2026 → Dec 2030 | substance-related disorder | Jacques E. Chelly | Withdrawn | No outcome recorded |
| Phase 0 | NCT06062628 | Jun → Dec 2026 expected | traumatic brain injury, traumatic encephalopathy | University of Texas Southwestern Medical Center | Recruiting | No outcome recorded |
| Phase 0 | NCT07294092 | Apr 2026 → Aug 2028 expected | — | Keith M Vogt | Recruiting | No outcome recorded |
| Phase 0 | NCT06788249 | Apr → Aug 2026 overdue | major depressive disorder | University of Pennsylvania | Recruiting | No outcome recorded |
| Phase 0 | NCT07429916 | Jan → Jun 2026 overdue | — | King Abdullah University Hospital | Recruiting | No outcome recorded |
| Phase 0 | NCT06935552 | Jun 2025 → Nov 2026 expected | — | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06665568 | Apr → Dec 2025 overdue | anxiety, major depressive disorder, sleep disorder | University of Zurich | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07040163 | Mar 2025 → Feb 2026 overdue | — | CAMC Health System | Active not recruiting | No outcome recorded |
| Phase 0 | NCT05344625 | Oct 2023 → Mar 2024 | anxiety disorder, cancer-related condition, depressive disorder | Northwell Health | Withdrawn | No outcome recorded |
| Phase 0 | NCT06001372 | Oct → Dec 2023 | anxiety, depressive disorder, digestive system cancer | University of Utah | Terminated | No outcome recorded |
| Phase 0 | NCT05410158 | May → Jul 2023 | — | Assiut University | Unknown | No outcome recorded |
| Phase 0 | NCT05796791 | May 2023 → Jun 2024 | nicotine dependence | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 0 | NCT05505630 | Jan 2023 → Dec 2025 | nicotine dependence | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 0 | NCT05327699 | Nov 2022 → Mar 2028 expected | major depressive disorder | Emory University | Recruiting | No outcome recorded |
| Phase 0 | NCT05086250 | Oct 2022 → Jul 2026 overdue | anxiety, malignant pancreatic neoplasm | Cedars-Sinai Medical Center | Recruiting | No outcome recorded |
| Phase 0 | NCT05468047 | Sep 2022 → Sep 2024 | perceptual disorders | Integrative Psychiatry Institute | Unknown | No outcome recorded |
| Phase 0 | NCT04928703 | May → Dec 2022 | — | ERP Biomarker Qualification Consortium | Completed | No outcome recorded |
| Phase 0 | NCT05217706 | Mar 2022 → Jan 2024 | depressive disorder | Rady Children's Hospital, San Diego | Unknown | No outcome recorded |
| Phase 0 | NCT06807554 | Jan 2022 | — | Liaquat National Hospital & Medical College | Completed | No outcome recorded |
| Phase 0 | NCT04977674 | Sep 2021 → Feb 2023 | major depressive disorder | King's College London | Completed | No outcome recorded |
| Phase 0 | NCT05097118 | Sep 2021 → May 2022 | appendicitis | Sohag University | Completed | No outcome recorded |
| Phase 0 | NCT04712071 | Feb 2021 → Feb 2022 | persian gulf syndrome | Baylor College of Medicine | Terminated | No outcome recorded |
| Phase 0 | NCT04562779 | Jan 2021 → Jan 2022 | alcohol dependence | Denver Health and Hospital Authority | Completed | No outcome recorded |
| Phase 0 | NCT04413799 | Sep 2020 → Dec 2024 | — | George Washington University | Terminated | No outcome recorded |
| Phase 0 | NCT03788694 | Jan 2020 | — | Bronx Veterans Medical Research Foundation, Inc | Withdrawn | No outcome recorded |
| Phase 0 | NCT04285684 | Dec 2019 → Jan 2021 | lactation disease | The Ketamine Research Foundation | Completed | No outcome recorded |
| Phase 0 | NCT04022226 | Oct 2019 → Oct 2020 | — | University of New Mexico | Completed | No outcome recorded |
| Phase 0 | NCT04099771 | Jul 2019 → Dec 2021 | major depressive disorder | The Miriam Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT03885427 | Mar → May 2019 | — | Zagazig University | Completed | No outcome recorded |
| Phase 0 | NCT03896256 | Mar 2019 → Jan 2020 | migraine disorder | Thomas Jefferson University | Completed | No outcome recorded |
| Phase 0 | NCT03573349 | Jan 2019 → Dec 2026 expected | bipolar depression, major depressive disorder | Mayo Clinic | Active not recruiting | No outcome recorded |
| Phase 0 | NCT03067974 | Sep 2017 → Jan 2019 | — | University of Arizona | Terminated | No outcome recorded |
| Phase 0 | NCT03090776 | Jul 2017 → Sep 2025 | chronic pain syndrome, neuropathy, painful | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 0 | NCT02836288 | Dec 2016 → May 2018 | cancer, depressive disorder | Scott A. Irwin, MD, PhD | Completed | No outcome recorded |
| Phase 0 | NCT02442739 | Aug 2016 → Nov 2017 | depressive disorder, head and neck cancer, malignant pancreatic neoplasm | Cedars-Sinai Medical Center | Withdrawn | No outcome recorded |
| Phase 0 | NCT02593643 | Jan 2016 → Apr 2017 | bipolar I disorder, bipolar II disorder, bipolar depression, major depressive disorder | Sunnybrook Health Sciences Centre | Completed | No outcome recorded |
| Phase 0 | NCT02414932 | Apr 2015 → Apr 2017 | depressive disorder | St Patrick's Hospital, Ireland | Completed | No outcome recorded |
| Phase 0 | NCT02083926 | Jan 2015 → Sep 2016 | social phobia | Yale University | Completed | No outcome recorded |
| Phase 0 | NCT03609190 | Jan 2015 → Dec 2018 | major depressive disorder | Psychiatric University Hospital, Zurich | Completed | No outcome recorded |
| Phase 0 | NCT02317341 | Dec 2014 → Mar 2019 | cancer | National Institute of Nursing Research (NINR) | Terminated | No outcome recorded |
| Phase 0 | NCT02037035 | Jul 2013 → Jun 2021 | depressive disorder | Yale University | Completed | No outcome recorded |
| Phase 0 | NCT03842800 | Apr 2013 → Aug 2018 | cognitive impairment with or without cerebellar ataxia | Yale University | Completed | No outcome recorded |
| Phase 175 trials | ||||||
| Phase 1 | NCT07683988 | Oct 2026 → Aug 2027 expected | major depressive disorder | Western University, Canada | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07691372 | Jun → Jul 2026 overdue | — | iX Biopharma Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05575999 | Jan → Oct 2026 expected | — | Kansas City Heart Rhythm Research Foundation | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07307768 | Dec 2025 → Dec 2027 expected | — | Soterix Medical | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06919198 | Sep 2025 → Aug 2028 | — | University of Wisconsin, Madison | Withdrawn | No outcome recorded |
| Phase 1 | NCT06935669 | Apr 2025 → Apr 2026 overdue | — | Ain Shams University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06767566 | Mar 2025 → Dec 2027 | postpartum depression | University of Utah | Suspended | No outcome recorded |
| Phase 1 | NCT06772753 | Feb 2025 → Jun 2027 expected | — | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 1 | NCT06698848 | Jan 2025 → Jun 2030 expected | depressive disorder | Massachusetts General Hospital | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06966596 | Nov 2024 → Mar 2025 | gallbladder disorder | Fazaia Ruth Pfau Medical College | Completed | No outcome recorded |
| Phase 1 | NCT06085937 | May 2024 → Apr 2026 overdue | depressive disorder | Lindsay Maguire, MD | Recruiting | No outcome recorded |
| Phase 1 | NCT05962424 | Oct 2023 → Sep 2030 expected | psychiatric disorder | Stanford University | Recruiting | No outcome recorded |
| Phase 1 | NCT06138691 | Oct 2023 → Jan 2025 | — | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT05907213 | Sep 2023 → Jun 2024 | postpartum depression | Grace Lim, MD, MS | Completed | No outcome recorded |
| Phase 1 | NCT06631625 | Sep 2023 → Sep 2024 | — | Alexandria University | Completed | No outcome recorded |
| Phase 1 | NCT05915013 | Sep 2023 → Dec 2032 expected | major depressive disorder, post-traumatic stress disorder | Yale University | Recruiting | No outcome recorded |
| Phase 1 | NCT05401227 | Oct 2022 → Aug 2028 expected | — | New York State Psychiatric Institute | Recruiting | No outcome recorded |
| Phase 1 | NCT05320107 | Jun 2022 → Feb 2025 | major depressive disorder | Medical University of Vienna | Unknown | No outcome recorded |
| Phase 1 | NCT05229653 | Apr → Oct 2022 | endometriosis | NYU Langone Health | Terminated | No outcome recorded |
| Phase 1 | NCT05051449 | Apr 2022 → Nov 2023 | depressive disorder, substance-related disorder | University of Maryland, Baltimore | Terminated | No outcome recorded |
| Phase 1 | NCT04861051 | Jul 2021 → Aug 2028 expected | epilepsy | Stanford University | Recruiting | No outcome recorded |
| Phase 1 | NCT04941040 | Jul → Oct 2021 | supratentorial cancer | Kasr El Aini Hospital | Completed | No outcome recorded |
| Phase 1 | NCT04714541 | Apr 2021 → Jul 2022 | anorexia nervosa | Homeostasis Therapeutics, LLC | Completed | No outcome recorded |
| Phase 1 | NCT05536362 | Feb 2021 → Jan 2022 | colon carcinoma | Egymedicalpedia | Completed | No outcome recorded |
| Phase 1 | NCT04876066 | Nov 2020 → Nov 2022 | — | West Virginia University | Unknown | No outcome recorded |
| Phase 1 | NCT04429685 | Nov 2020 → May 2021 | — | University of Texas Southwestern Medical Center | Terminated | No outcome recorded |
| Phase 1 | NCT04587778 | Oct 2020 → Mar 2025 | major depressive disorder | Medical University of Vienna | Unknown | No outcome recorded |
| Phase 1 | NCT04205890 | May 2020 | depressive disorder | Neurological Associates of West Los Angeles | Withdrawn | No outcome recorded |
| Phase 1 | NCT03973268 | Jan 2020 → Feb 2027 expected | major depressive disorder | National Institute of Mental Health (NIMH) | Recruiting | No outcome recorded |
| Phase 1 | NCT04082858 | Jan → Jun 2020 | major depressive disorder | St Patrick's Hospital, Ireland | Terminated | No outcome recorded |
| Phase 1 | NCT05421962 | Jan 2020 → Dec 2021 | — | Cantonal Hospital Zenica | Completed | No outcome recorded |
| Phase 1 | NCT04409665 | Jan 2020 → Mar 2022 | newborn respiratory distress syndrome | Medical University of Warsaw | Unknown | No outcome recorded |
| Phase 1 | NCT04032301 | Sep 2019 → Sep 2024 | major depressive disorder, post-traumatic stress disorder | University of Minnesota | Completed | No outcome recorded |
| Phase 1 | NCT04199468 | Sep 2019 → Jun 2022 | — | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT06021756 | Jul 2019 → Aug 2022 | Parkinson disease, drug-induced dyskinesia | University of Arizona | Unknown | No outcome recorded |
| Phase 1 | NCT03977675 | May 2019 → Jul 2020 | major depressive disorder | Columbia University | Terminated | No outcome recorded |
| Phase 1 | NCT03860831 | Mar → Jun 2019 | — | Ain Shams University | Unknown | No outcome recorded |
| Phase 1 | NCT03792672 | Feb → May 2019 | — | Neurocrine Biosciences | Completed | No outcome recorded |
| Phase 1 | NCT03721900 | Dec 2018 → Jun 2019 | major depressive disorder | Shenox Pharmaceuticals, LLC | Unknown | No outcome recorded |
| Phase 1 | NCT03367533 | Nov 2018 → Jul 2022 | bipolar disorder, major depressive disorder, post-traumatic stress disorder | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT03799900 | Nov 2018 → Mar 2019 | substance abuse | Naurex, Inc | Completed | No outcome recorded |
| Phase 1 | NCT03933865 | Oct 2018 → Feb 2022 | opiate dependence | University of California, San Francisco | Terminated | No outcome recorded |
| Phase 1 | NCT05444036 | Sep 2018 → May 2019 | — | Egymedicalpedia | Completed | No outcome recorded |
| Phase 1 | NCT03469089 | Mar → May 2018 | schizophrenia | University of Eastern Finland | Unknown | No outcome recorded |
| Phase 1 | NCT03256162 | Sep 2017 → Sep 2018 | bipolar depression, major depressive disorder | St Patrick's Hospital, Ireland | Completed | No outcome recorded |
| Phase 1 | NCT03065335 | May 2017 → Jan 2027 expected | major depressive disorder | National Institute of Mental Health (NIMH) | Recruiting | No outcome recorded |
| Phase 1 | NCT02652507 | Jun 2016 → May 2018 | — | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 1 | NCT03017248 | Jan → Jun 2016 | — | Faculty of Medicine, Sousse | Unknown | No outcome recorded |
| Phase 1 | NCT02611921 | Dec 2015 → May 2018 | autism spectrum disorder | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 1 | NCT02661061 | Dec 2015 → May 2018 | major depressive disorder | St Patrick's Hospital, Ireland | Terminated | No outcome recorded |
| Phase 1 | NCT02515890 | Nov 2015 → Dec 2018 | amnestic disorder | University of Pittsburgh | Completed | No outcome recorded |
| Phase 1 | NCT02501941 | Jul 2015 → Jan 2017 | subarachnoid hemorrhage, traumatic brain injury | University of New Mexico | Completed | No outcome recorded |
| Phase 1 | NCT02708849 | Jun 2015 → Mar 2020 | mental disorder | Yale University | Terminated | No outcome recorded |
| Phase 1 | NCT02577250 | May 2015 → Jun 2016 | major depressive disorder, post-traumatic stress disorder | Minneapolis Veterans Affairs Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT02289248 | Feb 2015 → Oct 2016 | depressive disorder | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT02341963 | Jan 2015 → Dec 2020 | — | Rush University Medical Center | Terminated | No outcome recorded |
| Phase 1 | NCT02494830 | Aug → Sep 2014 | — | University Medicine Greifswald | Completed | No outcome recorded |
| Phase 1 | NCT02165449 | Jun 2014 → Aug 2019 | major depressive disorder | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 1 | NCT02033434 | Mar 2014 → May 2016 | — | University of Calgary | Completed | No outcome recorded |
| Phase 1 | NCT01740492 | Sep 2012 → Jun 2014 | — | Rhode Island Hospital | Completed | No outcome recorded |
| Phase 1 | NCT01551329 | Mar 2012 → Nov 2015 | alcohol dependence, major depressive disorder | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT01500018 | Jan → Apr 2012 | substance abuse | AstraZeneca | Withdrawn | No outcome recorded |
| Phase 1 | NCT02378415 | Dec 2011 → Jun 2013 | depressive disorder | United States Naval Medical Center, San Diego | Terminated | No outcome recorded |
| Phase 1 | NCT01435213 | Sep 2011 → Jan 2012 | — | University of Turku | Completed | No outcome recorded |
| Phase 1 | NCT01369680 | May 2011 → Oct 2012 | chronic pain syndrome | University of Rochester | Completed | No outcome recorded |
| Phase 1 | NCT01209845 | Apr → Dec 2010 | depressive disorder | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT01165294 | Oct 2009 → May 2010 | schizophrenia | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 1 | NCT01736020 | Sep 2009 → Apr 2017 | — | Southern California Institute for Research and Education | Unknown | No outcome recorded |
| Phase 1 | NCT02675530 | Dec 2007 → Dec 2011 | schizophrenia | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT00662883 | Nov 2007 → Feb 2008 | — | Javelin Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00548964 | Oct 2007 → Jul 2013 | major depressive disorder | James Murrough | Completed | No outcome recorded |
| Phase 1 | NCT00520104 | Aug 2007 → Feb 2008 | — | Javelin Pharmaceuticals | Unknown | No outcome recorded |
| Phase 1 | NCT00520169 | Jul → Sep 2007 | — | Javelin Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00519987 | Jun → Aug 2007 | — | Javelin Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00618397 | Jun 2006 → Jun 2015 | substance-related disorder | University of Texas Southwestern Medical Center | Terminated | No outcome recorded |
| Phase 1/235 trials | ||||||
| Phase 1/2 | NCT07443254 | Mar 2026 → Apr 2027 expected | — | CAMC Health System | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07180095 | Jan → Jun 2026 overdue | — | Liaquat National Hospital & Medical College | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07247370 | Dec 2025 → Apr 2027 expected | alcohol-related disorders, major depressive disorder | South West Sydney Local Health District | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07482709 | Nov 2025 → Mar 2026 overdue | — | Liaquat National Hospital & Medical College | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07009158 | Oct 2025 → Sep 2029 expected | chronic pain syndrome, post-traumatic stress disorder | Queen's University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06597695 | Jul 2025 → Jul 2026 overdue | depressive disorder | Juliana Zambrano, MD, MPH | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05991232 | May 2025 → Apr 2028 | depressive disorder | Jay Fournier | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT06090422 | Jan 2025 → Jul 2027 expected | alcohol-related disorders, depressive disorder | University Hospital of North Norway | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06545890 | Aug → Nov 2024 overdue | delirium | Cairo University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06036511 | Dec 2023 | post-traumatic stress disorder | University of New Mexico | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT06031883 | Feb 2023 → Dec 2024 | — | Minia University | Completed | No outcome recorded |
| Phase 1/2 | NCT04955470 | Jun 2022 → Sep 2023 | — | University of British Columbia | Terminated | No outcome recorded |
| Phase 1/2 | NCT05168735 | Feb 2022 → Aug 2023 | major depressive disorder | Rebecca Price | Completed | No outcome recorded |
| Phase 1/2 | NCT05156060 | Jan 2022 → Dec 2025 overdue | head and neck carcinoma | Natalie Lockney | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04916548 | Sep 2021 → Jul 2023 | depressive disorder | Rebecca Price | Completed | No outcome recorded |
| Phase 1/2 | NCT04141696 | Jul 2021 → Mar 2024 | — | National Institute of Nursing Research (NINR) | Completed | No outcome recorded |
| Phase 1/2 | NCT04892251 | May 2021 → Dec 2023 overdue | opiate dependence | University of Utah | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04589208 | Jan 2021 → Jan 2027 expected | — | New York State Psychiatric Institute | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04388774 | Aug 2020 → Jun 2021 | ADNP-related multiple congenital anomalies - intellectual disability - autism spectrum disorder | Alexander Kolevzon | Completed | No outcome recorded |
| Phase 1/2 | NCT04179266 | Nov 2019 → May 2020 | cluster headache syndrome | CCH Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/2 | NCT04471818 | Sep 2019 → Jun 2023 | major depressive disorder | National Cancer Institute of Mexico | Completed | No outcome recorded |
| Phase 1/2 | NCT03813121 | Jun 2019 → Aug 2021 | nicotine dependence | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 1/2 | NCT03960658 | Apr → Nov 2019 | post-traumatic stress disorder | Minneapolis Veterans Affairs Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT04242914 | Feb 2019 → Feb 2021 | — | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
| Phase 1/2 | NCT03500289 | Aug 2018 → Aug 2019 | multiple sclerosis | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1/2 | NCT03237286 | Dec 2017 → Oct 2022 | depressive disorder | Rebecca Price | Completed | No outcome recorded |
| Phase 1/2 | NCT03146806 | Jul 2017 → Apr 2020 | cancer | Emory University | Completed | No outcome recorded |
| Phase 1/2 | NCT02258204 | Mar 2015 → Dec 2017 | stroke disorder | University Hospital, Caen | Unknown | No outcome recorded |
| Phase 1/2 | NCT02422290 | Mar 2015 → Feb 2018 | obsessive-compulsive disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT02461927 | Jan 2015 → Oct 2023 | alcohol dependence, major depressive disorder | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 1/2 | NCT01944293 | Sep 2013 → Sep 2017 | bipolar disorder, depressive disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT01535937 | Feb 2012 → Jan 2017 | cocaine dependence | New York State Psychiatric Institute | Terminated | No outcome recorded |
| Phase 1/2 | NCT01573741 | Feb → Dec 2012 | major depressive disorder | Shi Jinyun | Unknown | No outcome recorded |
| Phase 1/2 | NCT01089361 | Dec 2009 → Jun 2010 | infectious disease with sepsis | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00088699 | Jul 2004 → Jul 2017 | major depressive disorder | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 2137 trials | ||||||
| Phase 2 | NCT05945147 | Jan → Apr 2099 | complex regional pain syndrome | Stanford University | Withdrawn | No outcome recorded |
| Phase 2 | NCT07099534 | Sep 2026 → Sep 2028 expected | borderline personality disorder | University Hospital, Toulouse | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07112456 | Sep 2026 → Aug 2029 expected | acute asthma | Oman Medical Speciality Board | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07588802 | Jul 2026 → Apr 2027 expected | — | Massachusetts General Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06419985 | Jul 2026 → Jan 2028 expected | complex regional pain syndrome | University of Southern California | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07705022 | Jul 2026 → Jan 2028 expected | — | University of Michigan | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07569198 | Jun 2026 → Jan 2029 expected | bipolar depression, borderline personality disorder, major depressive disorder | Joshua Rosenblat | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06660017 | Jun 2026 → Jun 2027 expected | head and neck cancer | University of Oklahoma | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07247006 | Jun 2026 → Jan 2028 expected | atypical depressive disorder, chronic pain syndrome | University of Rochester | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07639359 | May 2026 → Jul 2027 expected | depressive disorder | Hospital Italiano de Buenos Aires | Recruiting | No outcome recorded |
| Show all 137 trials opens the full record — a long page | ||||||
| Phase 2/339 trials | ||||||
| Phase 2/3 | NCT07670507 | Jun → Dec 2026 expected | — | Albany Medical College | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07276542 | Jan → Dec 2026 expected | — | The Ketamine Research Foundation | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06048263 | Oct 2025 | postpartum depression | Washington University School of Medicine | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT07095842 | Aug 2025 → Jul 2026 overdue | epilepsy syndrome | Sohag University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07046611 | Jul 2025 → Jun 2026 overdue | epilepsy with generalized tonic-clonic seizures | Sohag University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06891300 | Apr 2025 → Oct 2026 expected | major depressive disorder | The Royal's Institute of Mental Health Research | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03223220 | Jul 2024 → Dec 2026 expected | ischemic stroke | Lower Merion Neurology Research Foundation | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06364072 | May 2024 → May 2025 | — | Cessatech A/S | Completed | No outcome recorded |
| Phase 2/3 | NCT05032118 | Apr 2023 | acquired aneurysmal subarachnoid hemorrhage | Jenna L Leclerc MD, PhD | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT05779657 | Mar 2023 → Aug 2024 | epilepsy with generalized tonic-clonic seizures | Sohag University | Completed | No outcome recorded |
| Phase 2/3 | NCT05696691 | Jan 2023 → Apr 2026 overdue | — | The University of Texas Health Science Center at San Antonio | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04939987 | Aug → Oct 2022 | — | Wake Forest University Health Sciences | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT05343507 | May 2022 → May 2025 | — | University of Liege | Unknown | No outcome recorded |
| Phase 2/3 | NCT04650074 | Nov 2021 → Jan 2024 | complex regional pain syndrome type 1, neuropathy, painful | Hospices Civils de Lyon | Completed | No outcome recorded |
| Phase 2/3 | NCT03436121 | Dec 2019 → Feb 2020 | depressive disorder | Maria Pacella | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT03889756 | Jul → Dec 2019 | major depressive disorder | Yale University | Terminated | No outcome recorded |
| Phase 2/3 | NCT04216888 | Jun 2019 → Dec 2020 | major depressive disorder | Dan Iosifescu | Completed | No outcome recorded |
| Phase 2/3 | NCT03553758 | Nov 2018 → Feb 2019 | — | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT02967640 | May 2018 → Dec 2024 | chronic pain syndrome, rotator cuff syndrome | Helse Møre og Romsdal HF | Completed | No outcome recorded |
| Phase 2/3 | NCT03407404 | Oct 2017 → Jun 2019 | — | Makerere University | Terminated | No outcome recorded |
| Phase 2/3 | NCT03086148 | Jul 2017 → Aug 2018 | — | Beijing Tiantan Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT03165149 | Jun 2017 → Aug 2019 | breast cancer | Assiut University | Completed | No outcome recorded |
| Phase 2/3 | NCT03499886 | Jan 2017 → Apr 2018 | — | Isfahan University of Medical Sciences | Unknown | No outcome recorded |
| Phase 2/3 | NCT03915938 | Jan → Nov 2017 | chronic pain syndrome, schizophrenia | Hospital de Clinicas de Porto Alegre | Completed | No outcome recorded |
| Phase 2/3 | NCT02783430 | Sep 2016 → Mar 2024 | depressive disorder | University Hospital, Lille | Completed | No outcome recorded |
| Phase 2/3 | NCT02636218 | Jan 2016 → Mar 2021 | subarachnoid hemorrhage | Unity Health Toronto | Completed | No outcome recorded |
| Phase 2/3 | NCT03000413 | Jun 2015 → Jun 2017 | asthma | Hospital Nossa Senhora da Conceicao | Completed | No outcome recorded |
| Phase 2/3 | NCT02514122 | Jun → Jul 2015 | — | University of Saskatchewan | Completed | No outcome recorded |
| Phase 2/3 | NCT02397889 | May 2015 → Jan 2020 | post-traumatic stress disorder | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 2/3 | NCT02929524 | Apr 2015 → Oct 2016 | digestive system disorder, respiratory system disorder | Hospital de Clinicas de Porto Alegre | Completed | No outcome recorded |
| Phase 2/3 | NCT02659085 | Feb 2015 → Aug 2019 | major depressive disorder | Pouya Movahed Rad | Completed | No outcome recorded |
| Phase 2/3 | NCT02398136 | Dec 2014 | post-traumatic stress disorder | Adriana Feder | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT02452060 | Oct 2014 → Apr 2017 | — | NYU Langone Health | Completed | No outcome recorded |
| Phase 2/3 | NCT02105415 | Apr 2014 → Nov 2017 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 2/3 | NCT02099006 | Nov 2013 → Jun 2015 | female reproductive system disorder | University of Rochester | Completed | No outcome recorded |
| Phase 2/3 | NCT02048423 | Jun 2013 → Jun 2015 | major depressive disorder | Nationwide Children's Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT01945047 | May 2013 → Dec 2017 | — | University of Ottawa | Completed | No outcome recorded |
| Phase 2/3 | NCT01807429 | Dec 2012 → Jan 2013 | dwarfism thin bones multiple fractures | Isfahan University of Medical Sciences | Completed | No outcome recorded |
| Phase 2/3 | NCT02969733 | Jan 2011 → Sep 2017 | neuropathy, painful | University Hospital, Lille | Completed | No outcome recorded |
| Phase 3104 trials | ||||||
| Phase 3 | NCT06835504 | Sep 2026 → Aug 2029 expected | — | Columbia University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07627906 | Jul → Dec 2026 expected | delirium | Cairo University | Recruiting | No outcome recorded |
| Phase 3 | NCT07530146 | May → Aug 2026 overdue | infectious disease with sepsis, pneumonia | Helwan University | Recruiting | No outcome recorded |
| Phase 3 | NCT06781697 | May 2026 → Dec 2027 expected | — | Sunnybrook Health Sciences Centre | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06907173 | Mar 2026 → Jun 2029 expected | — | University of Virginia | Recruiting | No outcome recorded |
| Phase 3 | NCT07450430 | Feb 2026 → Feb 2029 expected | sickle cell disease | Boston Children's Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07370181 | Jan → Jul 2026 overdue | — | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06767358 | Oct 2025 → Nov 2027 expected | — | McMaster University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07165262 | Aug 2025 → Mar 2027 expected | brain neoplasm, epilepsy | Children's Cancer Hospital Egypt 57357 | Active not recruiting | No outcome recorded |
| Phase 3 | NCT07088380 | Jul 2025 → Aug 2026 overdue | major depressive disorder | Vita-Salute San Raffaele University | Recruiting | No outcome recorded |
| Phase 3 | NCT06957704 | May 2025 → Apr 2028 expected | depressive disorder | Federal University of São Paulo | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05603104 | Apr 2025 → Jun 2028 expected | bipolar depression, major depressive disorder, schizophrenia | Dr. Inge Winter | Recruiting | No outcome recorded |
| Phase 3 | NCT06733129 | Apr 2025 → Apr 2027 expected | — | Nantes University Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT06464146 | Feb 2025 → Feb 2028 expected | — | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase 3 | NCT06713616 | Jan 2025 → Dec 2030 expected | depressive disorder | Yale University | Recruiting | No outcome recorded |
| Phase 3 | NCT06508710 | Oct 2024 → Mar 2026 overdue | major depressive disorder | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase 3 | NCT06752759 | Oct 2024 → Sep 2027 expected | major depressive disorder | Theresa Jacob, PhD, MPH | Recruiting | No outcome recorded |
| Phase 3 | NCT05973851 | Aug 2024 → Jun 2028 expected | major depressive disorder | Dr. Inge Winter | Recruiting | No outcome recorded |
| Phase 3 | NCT06383273 | May → Dec 2024 overdue | cataract | Melt Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT05625555 | Jan 2024 → Jul 2026 overdue | bipolar disorder, major depressive disorder | Abraham Nunes | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05783492 | Jan → Mar 2024 | — | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Withdrawn | No outcome recorded |
| Phase 3 | NCT06140927 | Dec 2023 → Dec 2026 expected | spinal stenosis | University of California, San Francisco | Recruiting | No outcome recorded |
| Phase 3 | NCT05437575 | Nov 2023 → Jul 2028 expected | — | Jason Sperry | Recruiting | No outcome recorded |
| Phase 3 | NCT06122948 | Nov 2023 → Oct 2024 | adenoid hypertrophy, drug allergy, tonsillitis | Kasr El Aini Hospital | Completed | No outcome recorded |
| Phase 3 | NCT05468840 | Jun → Dec 2023 | — | University of Ottawa | Unknown | No outcome recorded |
| Phase 3 | NCT05378555 | May 2023 → Jun 2026 overdue | sickle cell disease | Boston Children's Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT04833816 | Aug 2022 → Oct 2025 | — | Assistance Publique Hopitaux De Marseille | Completed | No outcome recorded |
| Phase 3 | NCT05481281 | Aug 2022 → Jan 2023 | — | Hamdard University | Unknown | No outcome recorded |
| Phase 3 | NCT04763343 | Jun 2022 → Feb 2027 expected | — | Tatiana Falcone, MD | Recruiting | No outcome recorded |
| Phase 3 | NCT05311722 | Apr → Dec 2022 | — | Sheikh Zayed Medical College | Unknown | No outcome recorded |
| Phase 3 | NCT05233566 | Apr 2022 → Mar 2023 | — | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 3 | NCT04939649 | Sep 2021 → Apr 2024 | bipolar depression, major depressive disorder | University of Dublin, Trinity College | Completed | No outcome recorded |
| Phase 3 | NCT04886453 | Aug 2021 → Mar 2024 | — | Centre Hospitalier Universitaire Dijon | Completed | No outcome recorded |
| Phase 3 | NCT04955158 | Aug 2021 → Feb 2023 | pharyngitis | Assiut University | Completed | No outcome recorded |
| Phase 3 | NCT04144933 | May 2021 → Jul 2024 | paralytic ileus | University of Saskatchewan | Unknown | No outcome recorded |
| Phase 3 | NCT04576975 | Apr → Dec 2021 | morbid obesity | Ain Shams University | Unknown | No outcome recorded |
| Phase 3 | NCT05163366 | Mar → Nov 2021 | — | Mbarara University of Science and Technology | Completed | No outcome recorded |
| Phase 3 | NCT04134052 | Jan → May 2021 | cognitive disorder | University of Colima | Unknown | No outcome recorded |
| Phase 3 | NCT04646694 | Nov 2020 → Mar 2023 | — | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 3 | NCT04227704 | Nov 2020 → Aug 2021 | postpartum depression | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 3 | NCT04176419 | Jan 2020 → Jun 2021 | — | Case Comprehensive Cancer Center | Terminated | No outcome recorded |
| Phase 3 | NCT04260607 | Jan 2020 → Apr 2021 | depressive disorder | Naval Medical Center Camp Lejeune | Terminated | No outcome recorded |
| Phase 3 | NCT03338205 | Jan 2020 → Dec 2021 | status asthmaticus | Augusta University | Withdrawn | No outcome recorded |
| Phase 3 | NCT04081545 | Dec 2019 → Mar 2023 | substance-related disorder | Christine Oryhan | Completed | No outcome recorded |
| Phase 3 | NCT03511833 | Dec 2019 → Dec 2021 | — | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT05386069 | Nov 2019 → Dec 2020 | — | Prisma Health-Upstate | Completed | No outcome recorded |
| Phase 3 | NCT04084548 | Oct 2019 → Dec 2025 overdue | — | The Cleveland Clinic | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04096768 | Sep 2019 → Sep 2021 | — | Lebanese American University Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT06185127 | Sep 2019 → May 2020 | lung disorder | University of Patras | Completed | No outcome recorded |
| Phase 3 | NCT04075006 | Aug 2019 → May 2021 | — | King Faisal Specialist Hospital & Research Center | Completed | No outcome recorded |
| Phase 3 | NCT03051945 | Aug 2019 | major depressive disorder | University of Utah | Withdrawn | No outcome recorded |
| Phase 3 | NCT03396601 | Jun 2019 → Dec 2024 | bipolar depression | NeuroRx, Inc. | Unknown | No outcome recorded |
| Phase 3 | NCT03751423 | Jun 2019 → Dec 2023 | — | Dr. Marie Eve Sophie Bussiere-Cote | Suspended | No outcome recorded |
| Phase 3 | NCT03674671 | Oct 2018 → Dec 2025 | bipolar depression, major depressive disorder | University of Ottawa | Suspended | No outcome recorded |
| Phase 3 | NCT03502421 | Sep 2018 → Sep 2019 | chronic pain syndrome | University of South Florida | Withdrawn | No outcome recorded |
| Phase 3 | NCT03525821 | Jul 2018 → Sep 2020 | — | Fondation Lenval | Completed | No outcome recorded |
| Phase 3 | NCT03539887 | May 2018 → Jan 2022 | alcohol abuse, depressive disorder | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 3 | NCT01519154 | Feb 2018 → Jun 2024 | — | Achim Schmitz | Completed | No outcome recorded |
| Phase 3 | NCT04322968 | Jan 2018 → Jun 2019 | chronic pain syndrome, post-traumatic stress disorder | VA Ann Arbor Healthcare System | Completed | No outcome recorded |
| Phase 3 | NCT03236805 | Nov 2017 → Nov 2022 | — | Nantes University Hospital | Terminated | No outcome recorded |
| Phase 3 | NCT02987985 | Oct 2017 → Sep 2019 | obstructive sleep apnea syndrome, respiratory underresponsiveness to hypoxia and hypercapnia | University of Saskatchewan | Completed | No outcome recorded |
| Phase 3 | NCT02828566 | Oct 2017 → Jan 2019 | disease of bone structure | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Unknown | No outcome recorded |
| Phase 3 | NCT02950233 | May 2017 → Dec 2018 | neuropathy, painful | Population Health Research Institute | Terminated | No outcome recorded |
| Phase 3 | NCT02920528 | May 2017 → Jun 2018 | chronic pain syndrome | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT03104140 | Apr 2017 → Apr 2018 | infectious disease with sepsis | Cairo University | Completed | No outcome recorded |
| Phase 3 | NCT02892916 | Mar 2017 → Aug 2019 | — | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT02532153 | Feb 2017 | — | Massachusetts General Hospital | Withdrawn | No outcome recorded |
| Phase 3 | NCT02752477 | Aug 2016 → Sep 2020 | chronic pain syndrome | Ben Lim | Unknown | No outcome recorded |
| Phase 3 | NCT02418702 | Aug 2016 | depressive disorder | United States Naval Medical Center, San Diego | Withdrawn | No outcome recorded |
| Phase 3 | NCT02735343 | Aug 2016 → May 2017 | headache disorder | Mike O'Callaghan Military Hospital | Terminated | No outcome recorded |
| Phase 3 | NCT02801292 | Jul 2016 → Jul 2018 | sickle cell disease | Augusta University | Unknown | No outcome recorded |
| Phase 3 | NCT03081416 | May → Sep 2016 | headache disorder | Brooke Army Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT02778880 | Mar 2016 → Feb 2017 | — | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 3 | NCT02402868 | Jan 2016 → Jan 2018 | disease of bone structure | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | No outcome recorded |
| Phase 3 | NCT02556606 | Oct 2015 → Mar 2020 | major depressive disorder | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 3 | NCT02431663 | Apr 2015 → Mar 2020 | — | Meyer Children's Hospital IRCCS | Terminated | No outcome recorded |
| Phase 3 | NCT02299440 | Apr 2015 → Nov 2019 | — | Nîmes University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT02591017 | Feb 2015 → Jul 2017 | — | University Hospital, Basel, Switzerland | Terminated | No outcome recorded |
| Phase 3 | NCT02079090 | Jul 2014 → Jun 2017 | — | University of British Columbia | Completed | No outcome recorded |
| Phase 3 | NCT02150161 | May 2014 → Aug 2015 | — | Clinica Santa Maria | Terminated | No outcome recorded |
| Phase 3 | NCT02062879 | Apr 2014 → Jun 2016 | — | University of Cincinnati | Terminated | No outcome recorded |
| Phase 3 | NCT01690988 | Feb 2014 → Jun 2016 | delirium | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 3 | NCT02037503 | Jan 2014 → May 2020 | major depressive disorder | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT02011347 | Jul 2013 → Oct 2015 | — | Hopital Foch | Terminated | No outcome recorded |
| Phase 3 | NCT01724983 | Jun 2012 → Jun 2014 | morbid obesity | University of Padova | Unknown | No outcome recorded |
| Phase 3 | NCT01557712 | Mar 2012 → Jan 2017 | major depressive disorder | University Hospital, Grenoble | Completed | No outcome recorded |
| Phase 3 | NCT01517828 | Jan 2012 → May 2016 | respiratory distress syndrome in premature infants | University Hospital, Montpellier | Unknown | No outcome recorded |
| Phase 3 | NCT01326325 | Jul 2011 → Feb 2013 | — | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT01983020 | Apr 2011 → Jan 2013 | — | Beth Israel Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT00474110 | Aug 2009 → Dec 2011 | mucositis | University of British Columbia | Withdrawn | No outcome recorded |
| Phase 3 | NCT01316744 | Apr 2009 → Oct 2011 | cancer | University of Glasgow | Unknown | No outcome recorded |
| Phase 3 | NCT00709436 | Jun 2008 → Aug 2011 | — | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00798083 | Apr 2008 → Jul 2009 | radiation-induced neuropathy | British Columbia Cancer Agency | Completed | No outcome recorded |
| Phase 3 | NCT00661063 | Apr 2008 → Apr 2009 | diabetic neuropathy | Irmandade da Santa Casa de Misericordia de Sao Paulo | Unknown | No outcome recorded |
| Phase 3 | NCT00516503 | Feb 2008 → Apr 2009 | cancer of unknown primary site, leukemia, lymphoproliferative syndrome, myelodysplastic syndrome +4 | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 3 | NCT00471445 | Oct 2007 → Sep 2013 | cancer of unknown primary site, chemotherapy-induced toxicity, peripheral neuropathy | Gary Morrow | Completed | No outcome recorded |
| Phase 3 | NCT00492388 | Jun 2007 → Aug 2011 | cancer | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT00484484 | May 2007 → Sep 2009 | — | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT00329394 | Apr 2006 → Sep 2008 | alcohol-induced mental disorder, head and neck carcinoma | University Hospital, Clermont-Ferrand | Suspended | No outcome recorded |
| Phase 3 | NCT00146926 | Sep 2005 → ? | — | Hospices Civils de Lyon | Unknown | No outcome recorded |
| Phase 3 | NCT00313378 | Apr 2004 → May 2008 | — | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 3 | NCT00210210 | Jan 2004 → Jul 2005 | breast cancer | Institut Bergonié | Completed | No outcome recorded |
| Phase 3 | NCT00224692 | Feb 2003 → Aug 2006 | cancer, mucositis | Assistance Publique - Hôpitaux de Paris | Terminated | No outcome recorded |
| Phase 3 | NCT00224588 | Jan 2003 → May 2005 | neuralgia | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 4206 trials | ||||||
| Phase 4 | NCT07670052 | Aug 2026 → Jun 2027 expected | — | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07682662 | Aug 2026 → Aug 2029 expected | sickle cell disease | University of Mississippi Medical Center | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07680140 | Jul 2026 → Sep 2028 expected | major depressive disorder | Weill Medical College of Cornell University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07139106 | May 2026 → May 2028 expected | major depressive disorder | New York State Psychiatric Institute | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07365800 | Apr → Dec 2026 expected | upper thoracic spina bifida aperta | University of Missouri-Columbia | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT07513935 | Mar → Sep 2026 expected | — | Ain Shams University | Active not recruiting | No outcome recorded |
| Phase 4 | NCT07182032 | Feb 2026 → Jun 2028 | chronic pain syndrome, endometriosis | University Hospitals Cleveland Medical Center | Withdrawn | No outcome recorded |
| Phase 4 | NCT06903819 | Nov 2025 → May 2027 expected | depressive disorder, post-traumatic stress disorder | Texas Tech University Health Sciences Center | Recruiting | No outcome recorded |
| Phase 4 | NCT06745388 | Jul 2025 → Sep 2026 expected | uterine disorder | Corewell Health East | Recruiting | No outcome recorded |
| Phase 4 | NCT06868589 | Jun 2025 → Jul 2026 overdue | — | Lahey Clinic | Active not recruiting | No outcome recorded |
| Show all 206 trials opens the full record — a long page | ||||||
| Phase not applicable148 trials | ||||||
| — | NCT07435493 | Nov 2026 expected | adenoid hypertrophy, obstructive sleep apnea syndrome | Ain Shams University | Not yet recruiting | No outcome recorded |
| — | NCT07708740 | Jul 2026 → Dec 2027 expected | — | Cairo University | Recruiting | No outcome recorded |
| — | NCT07636070 | Jun → Aug 2026 overdue | urolithiasis | murat sahin | Not yet recruiting | No outcome recorded |
| — | NCT06963294 | May → Jun 2026 overdue | delirium, subjective cognitive decline | Istinye University | Not yet recruiting | No outcome recorded |
| — | NCT06738043 | Apr 2026 → Apr 2027 expected | obesity disorder | Tanta University | Not yet recruiting | No outcome recorded |
| — | NCT07197684 | Mar → Dec 2026 expected | breast cancer, chronic pain syndrome | Aga Khan University | Not yet recruiting | No outcome recorded |
| — | NCT07385352 | Mar → Aug 2026 overdue | developmental dysplasia of the hip | Assiut University | Not yet recruiting | No outcome recorded |
| — | NCT07452705 | Feb 2026 → Jul 2027 expected | adolescent idiopathic scoliosis | University of Malaya | Not yet recruiting | No outcome recorded |
| — | NCT07381036 | Feb → Jul 2026 overdue | — | Sohag University | Not yet recruiting | No outcome recorded |
| — | NCT07640243 | Feb → May 2026 overdue | cancer, cholangitis | Ankara City Hospital Bilkent | Recruiting | No outcome recorded |
| Show all 148 trials opens the full record — a long page | ||||||
Also used as a comparator or background therapy in 443 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 011 trials | ||||||
| Phase 0 | NCT07408193 Comparator | Mar 2026 → Aug 2027 expected | refractory malignant neoplasm | National and Kapodistrian University of Athens | Recruiting | No outcome recorded |
| Phase 0 | NCT06368219 Comparator | Apr → Sep 2024 | — | Alexandria University | Unknown | No outcome recorded |
| Phase 0 | NCT06064162 Comparator | Dec 2023 → May 2025 | multiple sclerosis | Alta Bates Summit Medical Center | Completed | No outcome recorded |
| Phase 0 | NCT05671913 Comparator | Jan 2023 → Dec 2025 | — | Sanford Health | Withdrawn | No outcome recorded |
| Phase 0 | NCT05315271 Comparator | Jun 2022 → Jan 2023 | — | Sohag University | Completed | No outcome recorded |
| Phase 0 | NCT04437888 Comparator | Sep 2020 → Apr 2024 | neuropathy, painful, periprosthetic joint infection | Dartmouth-Hitchcock Medical Center | Completed | No outcome recorded |
| Phase 0 | NCT04016740 Background | Aug 2019 → Feb 2020 | coronary artery disorder, delirium | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 0 | NCT04018157 Comparator | Jul → Nov 2019 | — | Zagazig University | Completed | No outcome recorded |
| Phase 0 | NCT03088306 Comparator | Jul 2017 → May 2018 | lumbar disk degenerative disorder, lumbar spinal stenosis | Johns Hopkins University | Completed | No outcome recorded |
| Phase 0 | NCT03264430 Comparator | Jan 2017 → Oct 2018 | anal fistula, hemorrhoid | Esam Eldin Mohamed Abdalla | Unknown | No outcome recorded |
| Phase 0 | NCT03466242 Comparator | Jan 2017 → Jan 2020 | — | Phoenix Children's Hospital | Withdrawn | No outcome recorded |
| Phase 138 trials | ||||||
| Phase 1 | NCT07462559 Comparator | Mar → Dec 2026 expected | — | Helsinki University Central Hospital | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07669012 Comparator | Oct 2025 → Oct 2026 expected | — | Ain Shams University | Recruiting | No outcome recorded |
| Phase 1 | NCT07086690 Comparator | Apr 2025 → Apr 2027 expected | — | Ain Shams University | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06180759 Comparator | Jan → Sep 2025 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT07034911 Comparator | Apr → Sep 2024 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 1 | NCT06480201 Comparator | Jan 2024 → Dec 2026 expected | major depressive disorder | Texas A&M University | Recruiting | No outcome recorded |
| Phase 1 | NCT07248384 Comparator | Jul 2023 → Aug 2025 | neuropathy, painful | Liaquat National Hospital & Medical College | Completed | No outcome recorded |
| Phase 1 | NCT07248358 Comparator | Jun 2023 → Sep 2025 | acute cholecystitis | Liaquat National Hospital & Medical College | Completed | No outcome recorded |
| Phase 1 | NCT05828199 Comparator | Dec 2022 → Dec 2023 | nasal cavity polyp, nose, anomalous shape of | Al-Azhar University | Unknown | No outcome recorded |
| Phase 1 | NCT05591001 Comparator | Oct 2022 → Mar 2023 | tethered spinal cord syndrome | Cairo University | Completed | No outcome recorded |
| Phase 1 | NCT05314569 Comparator | Apr → Sep 2022 | — | Cairo University | Completed | No outcome recorded |
| Phase 1 | NCT05402189 Comparator | Feb → Jun 2022 | — | Ain Shams University | Unknown | No outcome recorded |
| Phase 1 | NCT04009759 Comparator | Oct 2021 → Jan 2025 | cardiac arrest | University Hospital, Akershus | Unknown | No outcome recorded |
| Phase 1 | NCT05049343 Background | Sep → Nov 2021 | — | Supernus Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05596669 Comparator | Sep 2021 → May 2022 | nephroma | Egymedicalpedia | Completed | No outcome recorded |
| Phase 1 | NCT04807335 Comparator | Mar → Jun 2021 | — | Cessatech A/S | Completed | No outcome recorded |
| Phase 1 | NCT04767035 Comparator | Dec 2020 → Jan 2021 | — | Melt Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT04678050 Comparator | Oct 2020 → Dec 2021 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 1 | NCT04485702 Comparator | Jul → Aug 2020 | — | Melt Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT04259476 Comparator | Jan → Jun 2020 | — | Services Institute of Medical Sciences, Pakistan | Unknown | No outcome recorded |
| Phase 1 | NCT03844906 Background | Dec 2018 → Mar 2019 | — | Supernus Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03814733 Comparator | Nov 2018 → Mar 2019 | — | Naurex, Inc | Completed | No outcome recorded |
| Phase 1 | NCT03771586 Background | Sep → Dec 2018 | — | Supernus Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03009409 Comparator | Mar → Oct 2018 | — | NeuroWave Systems Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02940509 Comparator | Jul 2017 → Feb 2018 | chronic pain syndrome | Milton S. Hershey Medical Center | Terminated | No outcome recorded |
| Phase 1 | NCT06867068 Comparator | Oct 2016 → Jun 2024 | — | Albert Einstein College of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT02935725 Background | Oct 2016 → Nov 2017 | schizophrenia | Autifony Therapeutics Limited | Completed | No outcome recorded |
| Phase 1 | NCT02401139 Comparator | Mar → Jul 2015 | major depressive disorder | The University of New South Wales | Completed | No outcome recorded |
| Phase 1 | NCT02515422 Comparator | Jun 2014 → May 2015 | — | Huseyin Aksoy | Completed | No outcome recorded |
| Phase 1 | NCT02033707 Background | Apr 2014 → Feb 2019 | — | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT01892189 Background | Aug 2013 → Aug 2014 | psychotic disorder | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT01749098 Comparator | Dec 2012 → Feb 2014 | schizophrenia | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT01794975 Comparator | Aug → Dec 2012 | — | University of Turku | Completed | No outcome recorded |
| Phase 1 | NCT01130909 Comparator | May 2010 → Jan 2011 | — | AstraZeneca | Terminated | No outcome recorded |
| Phase 1 | NCT01046630 Comparator | Dec 2009 → Mar 2011 | depressive disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00828659 Comparator | Dec 2008 → Apr 2009 | substance abuse | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00700076 Comparator | Jan 2008 → Mar 2009 | — | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT00690170 Comparator | Dec 2002 → Jun 2009 | — | Yale University | Completed | No outcome recorded |
| Phase 1/212 trials | ||||||
| Phase 1/2 | NCT06490731 Comparator | Apr → Jun 2026 overdue | — | New Valley University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05864053 Comparator | Sep 2024 → Dec 2026 expected | neuropathy, painful | Rush University Medical Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06077539 Comparator | Sep 2023 → Apr 2024 | subacute delirium | Cairo University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04686448 Comparator | Jan → Apr 2021 | — | Zagazig University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04621526 Comparator | Nov 2020 → Aug 2023 | — | Zagazig University | Completed | No outcome recorded |
| Phase 1/2 | NCT02935959 Comparator | Oct 2016 → Sep 2017 | childhood malignant neoplasm | Assiut University | Completed | No outcome recorded |
| Phase 1/2 | NCT02462681 Comparator | May 2015 → Dec 2016 | chronic pain syndrome | Assiut University | Completed | No outcome recorded |
| Phase 1/2 | NCT02065947 Background | Oct 2013 → Mar 2014 | — | Ramathibodi Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT01371110 Comparator | Jun 2012 → Jun 2015 | obsessive-compulsive disorder | Wayne Goodman MD | Terminated | No outcome recorded |
| Phase 1/2 | NCT01404442 Comparator | May → Nov 2011 | — | Qazvin University Of Medical Sciences | Completed | No outcome recorded |
| Phase 1/2 | NCT01198210 Comparator | Jul 2010 → Nov 2013 | — | Qazvin University Of Medical Sciences | Unknown | No outcome recorded |
| Phase 1/2 | NCT00611897 Comparator | Jan 2006 → Feb 2011 | cognitive disorder | Yale University | Completed | No outcome recorded |
| Phase 237 trials | ||||||
| Phase 2 | NCT06968546 Comparator | Feb 2026 → Mar 2028 expected | disease of bone structure | Fondation Lenval | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07369089 Background | Feb 2026 → Jan 2028 expected | substance-related disorder | University of California, San Diego | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06608277 Comparator | Jul 2025 → Dec 2027 expected | post-traumatic stress disorder | Northwestern University | Recruiting | No outcome recorded |
| Phase 2 | NCT06405607 Comparator | Jun 2025 → Apr 2028 expected | alcohol abuse, alcohol dependence | University of Iowa | Recruiting | No outcome recorded |
| Phase 2 | NCT05403086 Comparator | Jan 2025 → Dec 2026 expected | — | Charles S. Grob, M.D. | Recruiting | No outcome recorded |
| Phase 2 | NCT05421065 Comparator | Feb 2024 → Aug 2025 overdue | alcohol-related disorders | Peggy C Nopoulos | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05663801 Comparator | Dec 2022 → Dec 2023 | breast cancer | Beni-Suef University | Completed | No outcome recorded |
| Phase 2 | NCT05046184 Comparator | May 2022 → Apr 2025 | major depressive disorder | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT05133518 Comparator | Jul 2021 → Oct 2022 | cataract | Melt Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT04724759 Background | Jun 2021 → Apr 2023 | temporomandibular joint disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT05383313 Comparator | May 2021 → Apr 2025 | — | National Institute of Mental Health, Czech Republic | Unknown | No outcome recorded |
| Phase 2 | NCT04467424 Background | Jun → Nov 2020 | — | University Hospital of Split | Completed | No outcome recorded |
| Phase 2 | NCT03714919 Background | Aug → Nov 2019 | adenoid hypertrophy | Arlyne Thung | Completed | No outcome recorded |
| Phase 2 | NCT03756129 Comparator | Feb 2019 → Mar 2020 | major depressive disorder | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT03380442 Comparator | Sep 2018 → Jan 2020 | major depressive disorder | University of Helsinki | Unknown | No outcome recorded |
| Phase 2 | NCT03133780 Comparator | Jul 2018 → Mar 2020 | — | Assiut University | Completed | No outcome recorded |
| Phase 2 | NCT03395314 Comparator | Feb 2018 → May 2022 | borderline personality disorder | Yale University | Terminated | No outcome recorded |
| Phase 2 | NCT03233035 Comparator | Jan → Dec 2018 | — | University of Monastir | Completed | No outcome recorded |
| Phase 2 | NCT03290963 Comparator | Nov 2017 → Dec 2018 | — | William V. Bobo, M.D. | Withdrawn | No outcome recorded |
| Phase 2 | NCT02992496 Comparator | Apr 2017 → Dec 2020 | major depressive disorder | Medical University of Vienna | Unknown | No outcome recorded |
| Phase 2 | NCT03018301 Comparator | Jan → Jun 2017 | — | Assiut University | Unknown | No outcome recorded |
| Phase 2 | NCT02884440 Background | Nov 2016 → May 2019 | spondylolisthesis | Rennes University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT03296345 Comparator | Jun 2016 → Apr 2018 | sickle cell disease | UCSF Benioff Children's Hospital Oakland | Completed | No outcome recorded |
| Phase 2 | NCT02554253 Comparator | Sep 2015 → Dec 2020 | acute kidney injury, delirium | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT02418195 Comparator | Apr 2015 → Dec 2020 | major depressive disorder | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 2 | NCT02651792 Comparator | Jan 2015 → Apr 2016 | — | Assiut University | Completed | No outcome recorded |
| Phase 2 | NCT01920555 Comparator | Dec 2014 → Jan 2017 | — | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02199678 Comparator | Jul → Nov 2014 | — | Lotus Clinical Research, LLC | Completed | No outcome recorded |
| Phase 2 | NCT01809340 Background | Jun 2013 → Jul 2014 | depressive disorder | Janssen Research & Development, LLC | Terminated | No outcome recorded |
| Phase 2 | NCT01768767 Comparator | Jan 2013 | bipolar depression | Yale University | Withdrawn | No outcome recorded |
| Phase 2 | NCT01558063 Comparator | Feb 2012 → May 2015 | major depressive disorder | Columbia University | Completed | No outcome recorded |
| Phase 2 | NCT02284204 Background | Jan 2012 → Aug 2014 | — | Federal University of Goiás | Completed | No outcome recorded |
| Phase 2 | NCT01653327 Comparator | Jun 2010 → Aug 2016 | head and neck cancer, mucositis | Dartmouth-Hitchcock Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01100255 Comparator | Apr 2010 → Dec 2015 | obsessive-compulsive disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 2 | NCT00618423 Comparator | Oct 2007 → Mar 2013 | — | University Hospital, Geneva | Completed | No outcome recorded |
| Phase 2 | NCT00476151 Comparator | Jul 2007 → Apr 2008 | diabetic polyneuropathy, neuralgia | EpiCept Corporation | Completed | No outcome recorded |
| Phase 2 | NCT00475904 Comparator | Jul 2007 → Jun 2008 | postherpetic neuralgia | EpiCept Corporation | Completed | No outcome recorded |
| Phase 2/324 trials | ||||||
| Phase 2/3 | NCT06427707 Comparator | Jun → Oct 2024 overdue | esophageal varices with bleeding | Ain Shams University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06082076 Comparator | Nov 2023 → Nov 2024 | — | Assiut University | Unknown | No outcome recorded |
| Phase 2/3 | NCT05597878 Comparator | Apr 2023 → Feb 2026 | prostate cancer, substance-related disorder | Wake Forest University Health Sciences | Terminated | No outcome recorded |
| Phase 2/3 | NCT05229055 Comparator | Apr 2023 → May 2024 | — | University of Monastir | Completed | No outcome recorded |
| Phase 2/3 | NCT05727098 Comparator | Jan → Apr 2023 | breast cancer | National Cancer Institute, Egypt | Completed | No outcome recorded |
| Phase 2/3 | NCT06040060 Comparator | Dec 2022 → Mar 2023 | neuropathy, painful | Padjadjaran University | Completed | No outcome recorded |
| Phase 2/3 | NCT05508594 Comparator | Sep 2022 → Oct 2023 | — | Cessatech A/S | Completed | No outcome recorded |
| Phase 2/3 | NCT04704622 Comparator | Jan → Feb 2021 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 2/3 | NCT04195256 Comparator | Mar 2020 → Dec 2026 expected | — | Naveen Poonai | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03367988 Background | Dec 2018 → Jan 2023 | drug dependence | University of South Florida | Unknown | No outcome recorded |
| Phase 2/3 | NCT03115489 Comparator | May 2017 → Dec 2019 | epilepsy | University of Alabama at Birmingham | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT03113968 Comparator | Apr 2017 → Oct 2022 | major depressive disorder | Bo Hu | Completed | No outcome recorded |
| Phase 2/3 | NCT03060070 Comparator | Mar → Jun 2017 | — | Assiut University | Completed | No outcome recorded |
| Phase 2/3 | NCT03248648 Comparator | Mar → Sep 2017 | — | Assiut University | Completed | No outcome recorded |
| Phase 2/3 | NCT03063671 Comparator | Jan → Jul 2017 | — | Assiut University | Completed | No outcome recorded |
| Phase 2/3 | NCT02183272 Comparator | Aug 2016 → Nov 2017 | depressive disorder, impulse control disorder | University of Cincinnati | Unknown | No outcome recorded |
| Phase 2/3 | NCT03109418 Comparator | Jun 2016 → Sep 2018 | obstructive sleep apnea syndrome | University of Alabama at Birmingham | Terminated | No outcome recorded |
| Phase 2/3 | NCT02720406 Comparator | Apr 2016 → Dec 2018 | — | Assiut University | Completed | No outcome recorded |
| Phase 2/3 | NCT02726828 Comparator | Oct 2015 → Feb 2016 | — | Assiut University | Completed | No outcome recorded |
| Phase 2/3 | NCT02642497 Comparator | Aug 2015 → Feb 2016 | — | Assiut University | Completed | No outcome recorded |
| Phase 2/3 | NCT02514980 Comparator | Aug 2015 → Aug 2016 | — | Assiut University | Completed | No outcome recorded |
| Phase 2/3 | NCT02462174 Comparator | May → Sep 2015 | — | Assiut University | Completed | No outcome recorded |
| Phase 2/3 | NCT02455609 Comparator | Mar → Aug 2015 | — | Assiut University | Unknown | No outcome recorded |
| Phase 2/3 | NCT01504659 Comparator | Jul 2012 → Nov 2016 | bipolar disorder | Juvenile Bipolar Research Foundation | Terminated | No outcome recorded |
| Phase 345 trials | ||||||
| Phase 3 | NCT07590687 Comparator | Oct 2026 → Dec 2029 expected | — | Assistance Publique - Hôpitaux de Paris | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07573969 Comparator | May 2026 → May 2027 expected | — | Ain Shams University | Recruiting | No outcome recorded |
| Phase 3 | NCT07414706 Background | Mar 2026 → Jun 2028 expected | local anesthetic poisoning | Centre Hospitalier Universitaire, Amiens | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07330375 Comparator | Jan → Jun 2026 overdue | — | Zagazig University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07305883 Comparator | Dec 2025 → Jun 2026 overdue | — | Tehran University of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07194694 Comparator | Oct 2025 → Jan 2026 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 3 | NCT07120763 Comparator | Aug 2025 → Aug 2026 overdue | — | State University of New York at Buffalo | Recruiting | No outcome recorded |
| Phase 3 | NCT06873906 Comparator | Mar 2025 → Mar 2026 overdue | heart septal defect | Ain Shams University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06722742 Comparator | Sep → Dec 2024 overdue | — | Liaquat National Hospital & Medical College | Recruiting | No outcome recorded |
| Phase 3 | NCT06381063 Background | Mar 2024 → Mar 2027 expected | — | Centre Hospitalier Universitaire, Amiens | Recruiting | No outcome recorded |
| Phase 3 | NCT06871033 Comparator | Jan → Dec 2024 | — | Alexandria University | Completed | No outcome recorded |
| Phase 3 | NCT05802979 Comparator | Jan → Sep 2023 | — | Ain Shams University | Unknown | No outcome recorded |
| Phase 3 | NCT05674877 Comparator | Dec 2022 → Jun 2023 | cirrhosis of liver | Cairo University | Completed | No outcome recorded |
| Phase 3 | NCT04592809 Comparator | Oct 2022 → Jul 2025 | — | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT07043049 Comparator | Jun → Dec 2022 | benign shuddering attacks | Syed Muhammad Abbas | Completed | No outcome recorded |
| Phase 3 | NCT05306899 Comparator | Jun 2022 → Feb 2027 expected | headache disorder | University Health Network, Toronto | Recruiting | No outcome recorded |
| Phase 3 | NCT05887258 Background | May 2022 → May 2024 | — | Unai Ortega Mera | Completed | No outcome recorded |
| Phase 3 | NCT05444751 Background | Mar 2022 → Sep 2026 expected | lumbar disk disease, radiculopathy | Hospital for Special Surgery, New York | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT05037123 Comparator | Jan 2022 → May 2025 overdue | chronic pain syndrome | NYU Langone Health | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04797312 Comparator | Jul 2021 → Nov 2022 | local anesthetic poisoning | University Hospital, Angers | Unknown | No outcome recorded |
| Phase 3 | NCT04621110 Comparator | Jun → Sep 2021 | childhood malignant neoplasm | University of Sao Paulo General Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT04150757 Comparator | Dec 2019 → Oct 2020 | sickle cell disease | Abigail Nixon | Terminated | No outcome recorded |
| Phase 3 | NCT04013958 Comparator | Aug 2019 → Aug 2021 | urinary tract obstruction | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT03844984 Comparator | Feb → Sep 2019 | infectious disease with sepsis | Cairo University | Completed | No outcome recorded |
| Phase 3 | NCT03831854 Comparator | Jan 2019 → Dec 2020 | — | The Cleveland Clinic | Completed | No outcome recorded |
| Phase 3 | NCT03640468 Comparator | Dec 2018 → Jun 2019 | infectious disease with sepsis | Cairo University | Unknown | No outcome recorded |
| Phase 3 | NCT03729973 Comparator | Nov 2018 → Jan 2019 | pharyngitis | Zagazig University | Completed | No outcome recorded |
| Phase 3 | NCT03742557 Comparator | Oct 2018 → Jan 2020 | — | National Institute of Neurology and Neurosurgery, Mexico | Unknown | No outcome recorded |
| Phase 3 | NCT03513822 Comparator | Feb → Oct 2018 | chronic pain syndrome, neuralgia | Redar | Unknown | No outcome recorded |
| Phase 3 | NCT04095455 Comparator | Nov 2017 → Mar 2021 | — | National Cancer Institute, Egypt | Unknown | No outcome recorded |
| Phase 3 | NCT02866071 Comparator | Oct 2017 → Dec 2021 overdue | — | Jason McMullan | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04414800 Comparator | Apr 2017 → Mar 2018 | — | Isfahan University of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT04486690 Comparator | Jul 2016 → Jun 2017 | — | ghada fouad | Completed | No outcome recorded |
| Phase 3 | NCT02927379 Comparator | Jun → Dec 2016 | digestive system cancer | Assiut University | Completed | No outcome recorded |
| Phase 3 | NCT02311777 Comparator | May 2015 → Sep 2016 | pain agnosia | University of Texas Southwestern Medical Center | Withdrawn | No outcome recorded |
| Phase 3 | NCT02303847 Comparator | Nov 2014 → Jun 2015 | chronic pain syndrome | University of Washington | Unknown | No outcome recorded |
| Phase 3 | NCT02021240 Comparator | Feb 2014 → Sep 2015 | — | The University of Hong Kong | Completed | No outcome recorded |
| Phase 3 | NCT02726867 Comparator | Feb 2014 → Nov 2016 | epilepsy | Mid-Atlantic Epilepsy and Sleep Center, LLC | Withdrawn | No outcome recorded |
| Phase 3 | NCT03764267 Comparator | Jan 2014 → Jan 2017 | breast disorder | Ain Shams University | Completed | No outcome recorded |
| Phase 3 | NCT01951911 Comparator | Sep 2013 → Oct 2016 | neurological pain disorder | Haukeland University Hospital | Withdrawn | No outcome recorded |
| Phase 3 | NCT06310850 Comparator | Jun 2013 → Jan 2023 | — | Ankara Ataturk Sanatorium Training and Research Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01387139 Comparator | Jan 2011 → Jan 2014 | — | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 3 | NCT01211158 Comparator | Dec 2010 → Sep 2011 | — | Lions Gate Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01301079 Comparator | Sep 2010 → Sep 2012 | inflammatory disease | Federal University of São Paulo | Completed | No outcome recorded |
| Phase 3 | NCT00701909 Comparator | Jun 2008 → Apr 2009 | — | University of California, San Francisco | Completed | No outcome recorded |
| Phase 4149 trials | ||||||
| Phase 4 | NCT07427446 Comparator | Feb → Dec 2026 expected | delirium | Kasr El Aini Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT07214701 Comparator | Nov 2025 → Nov 2026 expected | varicocele | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07177235 Comparator | Nov 2025 → Jul 2027 expected | epilepsy | Thomas Jefferson University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07022821 Background | May → Aug 2025 overdue | — | Fatima Memorial Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06774274 Comparator | Mar 2025 → Mar 2026 overdue | neuropathy, painful, substance-related disorder | Universidad de Antioquia | Recruiting | No outcome recorded |
| Show all 149 trials opens the full record — a long page | ||||||
| Phase not applicable127 trials | ||||||
| — | NCT07486336 Comparator | Sep 2026 → Sep 2028 expected | cognitive disorder | Ente Ospedaliero Ospedali Galliera | Not yet recruiting | No outcome recorded |
| — | NCT07665463 Background | Jul → Dec 2026 expected | — | Jagiellonian University | Not yet recruiting | No outcome recorded |
| — | NCT07558226 Comparator | May 2026 → Nov 2027 expected | — | Fundacio Puigvert | Recruiting | No outcome recorded |
| — | NCT07520487 Comparator | Apr → Aug 2026 overdue | — | Cairo University | Recruiting | No outcome recorded |
| — | NCT07360327 Comparator | Jan → Dec 2026 expected | — | Ain Shams University | Not yet recruiting | No outcome recorded |
| Show all 127 trials opens the full record — a long page | ||||||
Evidence & citations 43 cited values
Every value below carries the sentence it was read from. 1,241 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Kétamine | “Before operation, all patients will receive Groups M and D, K will receive an oral administration of 0.2 mg/kg of midazolam (up to a maximum of 15 mg) and 4 µg/kg of...” NCT06879496 ↗1204“patients who will receive intravenous (I.V.) ketamine in a dose of 0.25 mg/kg diluted in 5 ml normal saline plus dexmetedomidine 0.25ug/kg followed by infusion of...” NCT07513935 ↗ “Ketamine produces dissociative anesthesia and sympathetic stimulation which provides more stable hemodynamic profile; however, ketamine is not widely used as a routine hypnotic...” NCT05166330 ↗ “General anesthesia without intraoperative opioids using dexmedetomidine, ketamine, lidocaine, sevoflurane, non-opioid co-analgesics, procedure-specific regional analgesia, and...” NCT07665463 ↗ “Opioid-Free Multimodal Analgesia will receive preoperative acetaminophen (15 mg/kg) and ibuprofen (10 mg/kg), intraoperative ketamine (0.5 mg/kg IV) and dexamethasone (0.1...” NCT07435493 ↗ “Ketamine, an FDA approved anesthetic agent, is becoming the sedative/analgesic of choice for emergency sedation in children because it causes deep sedation with minimal...” NCT00205712 ↗ “Intraoperative time: intravenous ketamine 0.5 mg kg-1, intravenous dexamethasone 8 mg Postoperative time: paracetamol 1 g every 6 hours a day, nefopam 20 every 8 hours a day,...” NCT06381063 ↗ “The patients will receive (slow intravenous injection) 0.3 mg/kg intravenous ketamine diluted by the pharmacy department into 10mL saline after the realization of PNB but...” NCT04890418 ↗ “Intravenous Induction of Anesthesia Using a Mixture of Ketamine and dexmedetomidine in a ratio of 1 mg ketamine to 0.5 ug dexmedetomidine given in a dose of 1mg/kg ketamine and...” NCT07002073 ↗ “NMDA active group will involve ketamine (0.5 mg/kg IV bolus pre-incision and 0.1 mg/kg/hr infusion postoperatively up to 24 hours) and oral memantine (5 mg BID [first week]; 10...” NCT02950233 ↗ “Open-label, Prospective Study to Assess the Safety, Tolerability, Analgesic Effect and Feasibility of Intranasal Sufentanil/Ketamine in Pediatric Patients With Moderate or...” NCT06364072 ↗ “Hallucinogens: DMT, 4-phosphoryloloxy-N-diethyltryptamine, dipropyltryptamine (DPT), ketamine, dextromethorphan, mescaline, PCP, psilocybin, salvinorin-A, LSD, d-lysergic acid...” NCT02033707 ↗ “participants received loading of ketamine 1 mg/kg and dexmedetomidine 1µg/kg over 10 minutes then continue by a dose of 0.25 mg/kg/hr ketamine and 0.25µg/kg/hr dexmedetomidine...” NCT04906772 ↗ “initially receiving nefopam and tramadol, implementing with ketamine if patients remain painful, and then implementing with remifentanil with escalating doses in case of...” PMID 39832962 ↗ Jan 2025 “Anesthesia will be maintained with Sevoflurane, Magnesium, Lidocaine, Ketamine, Decadron, Ondansetron, and Ketorolac at a concentration range/dose(s) based on the clinical need...” NCT03367988 ↗ “In addition to propofol as a hypnotic and rocuronium as a muscle relaxant, patients in the opioid-sparing group will receive Ketamine, Fentanyl, Lidocaine, Magnesium,...” NCT05485480 ↗ “Maintenance of general anesthesia: propofol infusion (50-150 μg.kg.min-1); ketamine infusion (up to 50 mg total); and inhaled anesthetic agent (isoflurane or sevoflurane) up to 0.5 MAC.” NCT05444751 ↗ “Intravenous administration of paracetamol 1 g, morphine 0.1 mg/kg, dexamethasone 8 mg, and ketamine 0.5 mg/kg bolus followed by 0.3 mg/kg/h infusion for postoperative pain management.” NCT07455565 ↗ “A Phase 2, Multiple-Dose Study of The Efficacy and Safety of Wafermine™ (Sublingual Ketamine) in Participants Experiencing Acute Post-Operative Bunionectomy or Abdominoplasty Pain” NCT03246971 ↗ “Ketamine is one of the few drugs available that has both sedative and analgesic properties and does not commonly compromise respiratory drive like opioids and sedative-hypnotics.” NCT06062628 ↗ “eligible patients will be randomly assigned to a double-blind administration of ketamine (0.5 mg/kg) or IV Saline, followed by the routine anesthetic agent and muscle relaxant.” NCT01260649 ↗ “Morphine 5 mg, ropivacaine 150 mg, tramadol 40 mg, epinephrine 1 mg, ketorolac 60 mg, and ketamine 1 g will be mixed with normal saline to prepare a total volume of 60 ml” NCT06113497 ↗ “Ketamine is an agent that is capable of providing both pain control and sedation while having either minimal effect on breathing or promoting spontaneous breathing.” NCT02643979 ↗ “Low-dose intravenous ketamine is an attractive opioid-sparing strategy because of its analgesic properties and favourable safety profile at analgesic doses.” PMID 42310772 ↗ Jun 2026 “Patients will receive a scalp block with a 20 ml syringe containing 1 mg/kg of 0.5% bupivacaine and 2 mg/kg of ketamine, with the rest filled with saline.” NCT07698665 ↗ “Anesthesia will be induced with IV ketamine, 2 mg/kg, fentanyl, 2 µg/kg, and rocuronium 0.9 mg/kg, administered to facilitate endotracheal intubation.” NCT06873906 ↗ “patients will receive 1mg / kg of Ketamine diluted by 20 ml saline (0.9 % ) and irrigated onto surgical field after hemostats and before skin closure.” NCT03165149 ↗ “Ketamine is an aryl cyclohexamine (2-0-chlorophenyl-2-methylamino cyclohexanone) synthesized in 1961, with sedative, amnesic and analgesic properties” NCT01651988 ↗ “Group (KD): patients will receive 1mg/kg ketamine and 1ug/kg dexmiditomidine in their respective loading syringes diluted in 20ml normal saline.” NCT05402189 ↗ “Patients will receive intraoperative ketofol (1:10 ratio of ketamine-propofol mixture) intravenous infusion with %90 of Mcfarlan dose regiment.” NCT05786833 ↗ “in this group the patients will receive ketamine 1-2 mg/kg IV slow ( Bioniche,Ireland Ketamine Hydrochloride 500mg/10cc)and titrated to effect.” NCT03349216 ↗ “Use of deeper plane of inhaled anesthetics or adjuncts (opioids, propofol, dexmedetomidine or ketamine for maintenance of general anesthesia.” NCT03962725 ↗ “Two syringes containing ketodex-ketamine (1 mg/kg) and dexmedetomidine (1 µg/kg)-each diluted with 0.9% saline and infused over 10 minutes.” NCT07246447 ↗ “Ketamine 0.5 mg/kg will be given post-induction of anaesthesia followed by infusion of 0.5 mcg/kg /hr in the Ketamine + Fentanyl group arm” NCT03052673 ↗ “All patients were administered a bolus of ketamine (0.5 mg/kg) and were started continuous infusion dexmedetomidine at a dose 0.7 μg/kg/h.” NCT05514652 ↗ “Patients will receive ketamine (sold in the form of Ketalar) intravenously, up to 0.75 µg/ml concentration, for a maximum of 90' minutes.” NCT05343507 ↗ “combination of medications may be used such as a local anesthesia, ibuprofen, acetaminophen, gabapentin, ketamine, lidocaine, and opioids” NCT04010266 ↗ “Patients are given 1 or 2 MKO melts (each contain 3mg midazolam, 25mg ketamine, 2mg ondansetron) sublingually before surgery for sedation” NCT03653520 ↗ “Ketamine, is also used as an anesthetic agent in ECT because it has a favorable seizure inducing effect and increased seizure duration.” NCT05408000 ↗ “In the Total i.v. anaesthesia (TIVA) group (n=60), patients underwent opioid-free TIVA with propofol, ketamine, and dexmedetomidine.” PMID 24554545 ↗ Feb 2014 “Peroperative opioid free anesthesia will be obtained via a combination of dexmedetomidine, ketamine, lidocaine and magnesium sulfate” NCT03124680 ↗ “Intravenous admixture prepared immediately before induction by combining equal parts of ketamine and propofol in the same syringe.” NCT07273851 ↗ “This study will compare the use of one drug (Propofol) versus the use of a combination of Propofol with another drug (Ketamine).” NCT01211158 ↗ “Ketofol which is a mixture of ketamine and propofol gains increasing interest as an agent for procedural sedation and analgesia” NCT04816162 ↗ “The unit's protocol includes drugs such as Morphine, Hydromorphone, Fentanyl, Clonidine, Ketamine, Midazolam and Acetaminophen.” NCT04538573 ↗ “the preventive effects of perioperative ketamine were tested in a randomized, double-blind, placebo-controlled clinical trial” PMID 18783971 ↗ Sep 2008 “Ketamine ® is supplied in 250 mg/5 ml vials containing sterile solution for dilution in sodium chlorure 0.9% for infusions.” NCT07590687 ↗ “single oral doses of lorcaserin (20, 40, and 60 mg), zolpidem (15 and 30 mg), ketamine (100 mg), and placebo was conducted” PMID 21412231 ↗ Mar 2011 “A bolus dose of ketamine of 0.35 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline.” NCT04622904 ↗ “continuous intravenous infusion of ketamine (5 μg/kg/min) and dexmedetomidine (0.6 μg/kg/h) during general anesthesia.” NCT07588802 ↗ “In the Ketofol group, 2 ml ketamine (50mg/ml) and 10 ml of propofol 1% (10mg/ml) were diluted in 8ml of normal saline.” NCT06212401 ↗ “Subanesthetic dose of intravenous ketamine (KET) has been found to be highly effective in rapid treatment depression” NCT06698848 ↗ “Each dose of MELT-300 will be provided as a single sublingual tablet, containing 3 mg midazolam and 50 mg ketamine.” NCT06383273 ↗ “The study group (OFA group) will receive a combination of clonidine, magnesium sulfate, ketamine, and lidocaine.” PMID 34838109 ↗ Nov 2021 “one under complete intravenous anesthesia (infusion of Propofol, Ketamine, Lignocaine and Dexmedetomidine)” NCT06390046 ↗ “Rectal Ketamine will be administered at 6 mg/kg and with a rectal nozzle it's infused through the rectum.” NCT05163366 ↗ “An opioid-free general anesthetic technique utilizing dexmedetomidine, ketamine, and lidocaine infusions” NCT02752477 ↗ “The subject will receive intravenous ketamine anesthesia at a dose of 0.5mg/kg delivered over 40 minutes” NCT02196259 ↗ “Kétamine is a derivated of phencyclidine with a sedative, anesthesic, analgesic and amnesiant activity.” NCT01517828 ↗ “Patients who received propofol (1mg/kg) plus ketamine (0.5mg/kg) at the induction of general anesthesia” NCT04365686 ↗ “Total intravenous anesthesia with propofol and dexmedetomidine hydrochloride and ketamine hydrochloride” NCT04144153 ↗ “Standard weight-based ketamine bolus (0.5 mg/kg) at procedure start, no Opioid rescue medications” NCT05386069 ↗ “the study drug ketamine or normal saline will be administered by one of the study team physicians” NCT06608277 ↗ “It is composed by Dexmedetomidine (Dexdor), Lidocaine, Magnesium Sulfate and ketamine (Ketolar).” NCT05887258 ↗ “OFA (n=159) consisting of intravenous ketamine, dexamethasone, lidocaine, and magnesium sulfate” PMID 42190101 ↗ May 2026 “Patient will received intravenous injection of precedex 0.25mic/Kg and ketamine 0,2 mg/kg .” NCT05705726 ↗ “The second group will receive a mixture that consists of Fentanyl, Propofol, and Ketamine.” NCT04473846 ↗ “consists of patients receiving Serratus anterior plane block using Bupivacaine + Ketamine.” NCT05802979 ↗ “single dose IV Ketamine (Ketalar) 0.5mg/kg in 100ml Normal Saline infused over 40 minutes” NCT04260607 ↗ “A mixture of 5 mcg/ml of Fentanyl, 5 mg/ml of Propofol, and 5 mg/ml of Ketamine was used.” NCT04285528 ↗ “Sedation based on dexmedetomidine and low dosage of ketamine, avoiding GABAergic-drugs” NCT07486336 ↗ “0.5mg/kg of ketalar (ketamine). Single, intravenous, steady state infusion over 40min.” NCT04656886 ↗ “Single administration of Ketalar® (ketamine hydrochloride injection, USP); 5 mg/kg, IM” NCT03375671 ↗ “Afterwards a continuous intravenous infusion of lidocaine and ketamine was started:” NCT04355468 ↗ “a second continuous parenteral sedative agent (midazolam, propofol, or ketamine)” NCT06549426 ↗ “0.5 mg/kg Ketamine IV, and 2 minutes later receive 1 mg/kg Propofol (Diprivan).” NCT02079090 ↗ “Patients will receive Ketofol (propofol- ketamine mixture in a ratio of 1:1).” NCT07627906 ↗ “ketofol mixture 0.3 ml/kg (propofol 25 µg /kg/min and ketamine 10 µg/kg/min)” NCT03764267 ↗ “Ketamine isn't only an anesthetic agent but also has an analgesic effect.” NCT04987372 ↗ “Ketamine 2mg/kg IV + Atropine 0.01mg/kg or Same volume of Normal saline” NCT00834470 ↗ “Ketamine is a sedative premedication that is commonly used in children.” NCT07461376 ↗ “low-dose ketamine for analgesia and prevention of central sensitization” NCT07310524 ↗ “Ketamine is an anaesthetic agent with potent analgesic properties.” NCT02462681 ↗ “dilution containing 9.5 mL of 1% propofol + 0.5 mL of 5% ketamine” NCT05473949 ↗ “Proprietary oral formulation of 486mg aspirin and 80mg ketamine” NCT05615948 ↗ “50 mg Ketamine 500 mg Lidocaine (25 ml of standard 2% solution)” NCT06343753 ↗ “0.5 to 1.5 mg/kg of ketamine are administered intramuscularly” NCT04892251 ↗ “ketamine 4% amitriptyline 2% cream, twice daily for 4 weeks” NCT00475904 ↗ “Sufentanil 0.5 mcg/kg + ketamine 0.5 mg/kg as nasal spray” NCT04897750 ↗ “or ketamine 2mg/kg (if there is intravenous (IV) access)” NCT03408340 ↗ “ketamine 25 mg/h for a max of 50 mg during the procedure” NCT05962671 ↗ “ketamine Hydrochloride, Serial# 5751304560, DIN 02246796” NCT04123652 ↗ “1. IV dexmedetomidine 2. IV ketamine Both for sedation” NCT03954379 ↗ “Propofol 2-3mg/kg, Ketamine 1-1.5mg/kg, Hyoscine 10mg” NCT04894864 ↗ “Multimodal IV analgesia of lidocaine, ketamine and MS” NCT06661746 ↗ “K= Kétamine P= Propofol RSS= Ramsay Sedation Score” NCT01544725 ↗ “Ketamine loading dose 0.25 mg/kg i.v. infusion.” NCT04941040 ↗ “group (F) receive dexmedetomidine and ketamine” NCT07360327 ↗ “propofol 6.4 mg/kg/h ketamine 10 microg/kg/min” NCT01501786 ↗ “TCI propofol mixed with clonidine and ketamine” NCT05536362 ↗ “Propofol 0.25 mg/kg + Ketamine 0.25mg/kg IV” NCT07530146 ↗ “Ketamine 0.5mg/kg IV bolus (based on IBW)” NCT04081545 ↗ “ketamine (25-50 mcg) prior to intubation” NCT07211399 ↗ “Sufentanil 0.2 µg/kg; Ketamine 0.5 mg/kg” NCT07414706 ↗ “ketamine delivered by transdermal patch” NCT03721900 ↗ “Lidocaine, Propofol, Ketamine, Hyoscine” NCT05172739 ↗ “SAGE-718 in combination with Ketamine” NCT03844906 ↗ “SAGE-718 in combination with Ketamine” NCT03771586 ↗ “ketamine iv bolus dose of 0.35 mg/kg” NCT06736496 ↗ “0.3 mg/kg ketamine in 10 ml volume” NCT05752799 ↗ “open-label ketamine infusion” NCT03973268 ↗ “Ketamine: 0.25-0.5mg/Kg” NCT07558226 ↗ “0.3 mg/kg Ketamine” NCT07568938 ↗ “KETAMINE 0,15mg/kg” NCT02884440 ↗ “Drug: Ketamine” NCT02462174 ↗ “Drug: Ketamine” NCT04576975 ↗ “Ketamine alone” NCT05133518 ↗ “ketamine” NCT03596424 ↗ “Ketamine” NCT06366334 ↗ |
| Known as | (R,S)-ketamine | “Subanesthetic-dose racemic (R,S)-ketamine (ketamine) produces rapid, robust, and sustained antidepressant effects in major depressive disorder (MDD) and bipolar disorder (BD)...” PMID 35501309 ↗ May 20222“Participants will undergo one infusion of ketamine as active comparator. (R,S-ketamine 50mg/ml solution for injection, dose: 0,5 mg per kg bodyweight)” NCT05577585 ↗ “intranasal (IN) racemic (R,S)-ketamine had antisuicidal and antidepressant effects” PMID 38696221 ↗ Apr 2024 |
| Known as | dexter ketamine | “Drug: dexter ketamine” NCT02953210 ↗ |
| Known as | INK | “The purpose of this study is to determine if Intranasal Ketamine (INK) is efficacious for Procedural Sedation and Analgesia (PSA) when compared to Intravenous Ketamine (IVK) in...” NCT03781817 ↗ |
| Known as | IVK | “The purpose of this study is to determine if Intranasal Ketamine (INK) is efficacious for Procedural Sedation and Analgesia (PSA) when compared to Intravenous Ketamine (IVK) in...” NCT03781817 ↗ |
| Known as | KET | “The purpose of this study is to examine the effectiveness of a single infusion of ketamine (KET), to determine which dose is optimal 7 days after infusion using Bayesian...” NCT02556606 ↗7“The clinical team will test whether the effects of ketamine (KET) on mood and psychotic states is modified by co-administration with sodium nitroprusside (NP) in patients with...” NCT03102736 ↗ “Subanesthetic dose of intravenous ketamine (KET) has been found to be highly effective in rapid treatment depression” NCT06698848 ↗ “All participants will receive three intravenous (IV) Ketamine (KET) infusions over 7 days.” NCT03290963 ↗ “Ketamine (KET) has been used for decades as a sedative and anesthetic.” NCT01945047 ↗ “Levetiracetam (LEV) (60 mg/Kg) + 1 mg/kg Ketamine (KET)” NCT06907173 ↗ “Subanesthetic dose intravenous ketamine (KET)” NCT06034821 ↗ “Group A will receive rectal ketamine(Ket)” NCT05163366 ↗ |
| Known as | KET01 | “Treatment with Ketamine Hydrochloride Prolonged-Release Tablets (KET01, 240 mg)” NCT07396272 ↗ |
| Known as | Ketalar | “Ketamine (ketalar®) will be administrated by intravenous route in 1mg/kg dose and the study will use this drug to compare the efficiency of intranasal drugs.” NCT04621110 ↗20“Its hydrochloride salt is marketed under many brand names such as Ketanest, Ketalar, or Ketaset.” NCT02494830 ↗ “Low dose ketamine - Ketalar (Racemic Ketamine Hydrochloride) Saline - Isotonic/Normal Saline” NCT04429685 ↗ “Ketamine 1 mg /kg(ketalar Vial 50mg/ml pfzer com) will be administered IV before induction” NCT07074262 ↗ “single dose IV Ketamine (Ketalar) 0.5mg/kg in 100ml Normal Saline infused over 40 minutes” NCT04260607 ↗ “0.5mg/kg of ketalar (ketamine). Single, intravenous, steady state infusion over 40min.” NCT04656886 ↗ “Single administration of Ketalar® (ketamine hydrochloride injection, USP); 5 mg/kg, IM” NCT03375671 ↗ “Ketalar (Ketamin, Pfizer) and Dormicum (Midazolam, Roche)” NCT02732132 ↗ “Ketamine (Ketalar, an FDA-approved drug for anesthesia)” NCT02252432 ↗ “Ketamine (Ketalar) Dose Level 1” NCT05907213 ↗ “Drug: Ketamine (Ketalar)” NCT05105061 ↗ “Ketamine (Ketalar)” NCT06767566 ↗ “Ketalar (ketamine)” NCT01551329 ↗ “Ketamine (Ketalar)” NCT03380442 ↗ “Ketalar™” NCT01892189 ↗ |
| Known as | Ketamin | “Ketalar (Ketamin, Pfizer) and Dormicum (Midazolam, Roche)” NCT02732132 ↗ |
| Known as | Ketamine (Hydrochloride) HCL | “Participants will be randomized to (1) Ketamine (Hydrochloride) HCL; (2) psychotherapy (using Cognitive Behavioral Therapy); or (3) a combination of Ketamine HL and psychotherapy.” NCT05639322 ↗ |
| Known as | Ketamine (Ketalar) 50mg/mL injection | “Ketamine (Ketalar) 50mg/mL injection” NCT02267980 ↗ |
| Known as | KETAMINE 50 mg/ml ATC N01AX03 Marketing Authorisation number 47034 | “KETAMINE 50 mg/ml ATC N01AX03 Marketing Authorisation number 47034” NCT02909049 ↗ |
| Known as | ketamine HCl | “Group A received PCA ketamine (Ketamine HCl, Pfizer Inc., US) 0.5 mg plus morphine 0.5 mg ml-1 (ratio 1:1) while Group B received PCA morphine (Pfizer Inc., US) 1 mg ml-1 as...” NCT06021717 ↗6“10mg/kg of Ketamine Hcl 100Mg/Ml Inj to be administered intranasally for pediatric procedural sedation” NCT03067974 ↗ “IV NRX-100 (ketamine HCL) for rapid stabilization of symptoms of depression and suicidal ideation” NCT03396601 ↗ “PCA ketamine (Ketamine HCl, Pfizer Inc., US) 0.5 mg plus morphine 0.5 mg ml-1 (ratio 1:1)” NCT06010056 ↗ “Ketamine-HCL IV 1mg/kg (up to 100 mg) over 2 hours, on weeks 2, 7, and 12.” NCT05639322 ↗ “PMI-150 (intranasal ketamine HCl)” NCT00662883 ↗ “Ketamine Hcl 50Mg/Ml Inj” NCT03499886 ↗ |
| Known as | Ketamine HCl Prolonged Release | “Administration of Ketamine HCl Prolonged Release - 40mg BID” NCT06419985 ↗ |
| Known as | Ketamine Hydrochloride | “Patients will be given ultrasound guided, modified Pecs block with 30 mL of 0.25% bupivacaine hydrochloride (Markyrene ®Sigma Tec, Egypt) plus ketamine hydrochloride (1 mg/kg)...” NCT05410158 ↗70“This double-blind, crossover, placebo-controlled study analyzed data from 18 drug-free major depressive disorder subjects and 18 heathy controls who received a single i.v....” PMID 29668918 ↗ Aug 2018 “METHODS: In a randomized, double-blind, crossover study, 20 patients with major depression were randomly assigned, and 18 completed 2 treatment days with intranasal ketamine...” PMID 24821196 ↗ Apr 2014 “A Randomized, Double-Blind, Placebo-Controlled Pilot Study of the Safety and Efficacy of 10 mg, 30 mg, and 50 mg of Transnasal Ketamine Hydrochloride (PMI-100) for the...” NCT00488787 ↗ “The study agent is a mouthwash preparation of ketamine hydrochloride 20mg/5ml in NovaFilm suspension with OraSweet flavoring agent, which will be administered via swish and...” NCT05331131 ↗ “Ketamine hydrochloride (1 mg/kg) added to bupivacaine 0.25% (0.5 mL/kg) administered by ultrasound-guided quadratus lumborum block during open pyeloplasty.” NCT07596810 ↗ “in this group the patients will receive ketamine 1-2 mg/kg IV slow ( Bioniche,Ireland Ketamine Hydrochloride 500mg/10cc)and titrated to effect.” NCT03349216 ↗ “subjects were given an intravenous infusion of either ketamine hydrochloride (0.5 mg/kg) or placebo on 2 test days, a week apart.” PMID 16894061 ↗ Aug 2006 “comparing ketamine hydrochloride (20 mg, followed by 10 mg every 5 minutes) with morphine sulfate (2 or 3 mg every 5 minutes)” PMID 38285446 ↗ Jan 2024 “55 patients will receive ketamine hydrochloride, over six infusions, flexibly dosed between 0.5 mg/kg to 0.85 mg/kg.” NCT06480500 ↗ “Patients will receive IV ketamine hydrochloride in a dose of 0.5 mg/kg (equivalent to 0.4 ml/kg) over 10 min.” NCT05565664 ↗ “ketamine hydrochloride 250microgram/ ml for iv injection after 30 minutes of stable isoflurane anesthesia” NCT03290495 ↗ “Intravenous infusion of ketamine hydrochloride (0.5 mg/kg) and midazolam (0.045 mg/kg).” PMID 24740528 ↗ Jun 2014 “Treatment with Ketamine Hydrochloride Prolonged-Release Tablets (KET01, 240 mg)” NCT07396272 ↗ “A total of 20 mg of Ketamine Hydrochloride will be administered intravenously” NCT03621085 ↗ “Six infusions of 0.5 mg/Kg of ketamine hydrochloride solution over 2 weeks.” NCT02577250 ↗ “Patients will receive 0.5 mg/kg intravenous ketamine hydrochloride.” NCT07708740 ↗ “Flexible-dose intranasal ketamine hydrochloride (5 - 50 mg)” NCT06665568 ↗ “dose 0.5mg/kg of IV Ketamine Hydrochloride over 40 min” NCT05019885 ↗ “Ketamine Hydrochloride 50Mg/1mL Solution for Injection” NCT03499886 ↗ “Drug: Ketamine Hydrochloride” NCT05378555 ↗ “Drug: Ketamine Hydrochloride” NCT06066879 ↗ “Drug: Ketamine Hydrochloride” NCT05339074 ↗ “Drug: ketamine hydrochloride” NCT06891300 ↗ “Drug: Ketamine Hydrochloride” NCT04712071 ↗ “Drug: Ketamine Hydrochloride” NCT03596424 ↗ “Drug: Ketamine Hydrochloride” NCT05962424 ↗ “Drug: Ketamine Hydrochloride” NCT05046184 ↗ “Drug: Ketamine Hydrochloride” NCT02571491 ↗ “Drug: Ketamine Hydrochloride” NCT05437575 ↗ “Drug: Ketamine Hydrochloride” NCT05032118 ↗ “Drug: Ketamine Hydrochloride” NCT05051449 ↗ “Drug: Ketamine Hydrochloride” NCT06091657 ↗ “Drug: Ketamine Hydrochloride” NCT05026203 ↗ “Drug: Ketamine Hydrochloride” NCT03290625 ↗ “Drug: Ketamine Hydrochloride” NCT02817477 ↗ “Drug: ketamine hydrochloride” NCT06767358 ↗ “Drug: Ketamine Hydrochloride” NCT04589208 ↗ “Drug: Ketamine Hydrochloride” NCT05552391 ↗ “Drug: Ketamine Hydrochloride” NCT05803551 ↗ “Drug: Ketamine Hydrochloride” NCT06496750 ↗ “Drug: Ketamine Hydrochloride” NCT07088380 ↗ “Drug: Ketamine Hydrochloride” NCT05796791 ↗ “Drug: Ketamine Hydrochloride” NCT04850911 ↗ “Drug: Ketamine Hydrochloride” NCT05360030 ↗ “Drug: Ketamine Hydrochloride” NCT06366334 ↗ “Drug: Ketamine Hydrochloride” NCT03410446 ↗ “Drug: Ketamine Hydrochloride” NCT07569198 ↗ “Drug: Ketamine Hydrochloride” NCT05175781 ↗ “Drug: Ketamine Hydrochloride” NCT05004896 ↗ “Drug: Ketamine Hydrochloride” NCT03396601 ↗ “Drug: Ketamine Hydrochloride” NCT05383313 ↗ “Ketamine Hydrochloride” NCT05973851 ↗ |
| Known as | Ketamine hydrochloride (Ketamin Inresa 2 ml) | “Ketamine hydrochloride (Ketamin Inresa 2 ml)” NCT06410599 ↗ |
| Known as | Ketamine hydrochloride, Ketalar | “Ketamine hydrochloride, Ketalar” NCT07536633 ↗ |
| Known as | Ketamine hydrochrolide 50mg/ml,Nirma Pharmaceuticals (India) | “Ketamine hydrochrolide 50mg/ml,Nirma Pharmaceuticals (India)” NCT02434939 ↗ |
| Known as | Ketamine Injectable Product | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03498391 ↗ |
| Known as | Ketamine PR | “All subjects will start with 40mg BID of Ketamine PR (80 mg/day) on the Baseline visit.” NCT06419985 ↗ |
| Known as | Ketamine Sigma-Tec | “Patients will be given ultrasound guided, modified Pecs block with 30 mL of 0.25% bupivacaine hydrochloride (Markyrene ®Sigma Tec, Egypt) plus ketamine hydrochloride (1 mg/kg)...” NCT05410158 ↗ |
| Known as | Ketamine sulphate | “Group B:Ketamine group(25 patients) will receive 0.5 mg/Kg ketamine sulphate in 100 ml normal saline given in 40 minutes with 20 minutes follow up to obverse any delayed...” NCT06184958 ↗ |
| Known as | Ketamine, Ketamin (Cristalia Lab, Sao Paulo, Brazil) | “Ketamine, Ketamin ® (Cristalia Lab, Sao Paulo, Brazil)” NCT02284204 ↗ |
| Known as | Ketanest | “Its hydrochloride salt is marketed under many brand names such as Ketanest, Ketalar, or Ketaset.” NCT02494830 ↗ |
| Known as | Ketanest-S | “Patients will receive either nebulized placebo (i.e. saline) or ketamine (Ketanest-S) when they require pain alleviation in the PACU.” NCT02397356 ↗ |
| Known as | Ketaset | “Its hydrochloride salt is marketed under many brand names such as Ketanest, Ketalar, or Ketaset.” NCT02494830 ↗ |
| Known as | Ketolar | “It is composed by Dexmedetomidine (Dexdor), Lidocaine, Magnesium Sulfate and ketamine (Ketolar).” NCT05887258 ↗ |
| Known as | LDK | “Patients were consented and randomized to receive, either IV ketamine (LDK) 1 mg/kg or IV morphine (MOR) 0.1 mg/kg as an infusion over 10 min.” PMID 29794277 ↗ Jan 2018 |
| Known as | nKTM | “OBJECTIVE: To compare the effectiveness of sedation by intranasal administration of midazolam (nMDZ) or ketamine (nKTM) for neonatal intubation.” PMID 28818854 ↗ Aug 2017 |
| Known as | NRX100 | “Administration of Intravenous NRX100 (Ketamine) vs Placebo Infusion for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Patients With Bipolar Depression” NCT03396601 ↗ |
| Known as | PMI-100 | “A Randomized, Double-Blind, Placebo-Controlled Pilot Study of the Safety and Efficacy of 10 mg, 30 mg, and 50 mg of Transnasal Ketamine Hydrochloride (PMI-100) for the...” NCT00488787 ↗ |
| Known as | PMI-150 | “30 mg PMI-150 (intranasal ketamine)” NCT00519987 ↗ |
| Known as | Racemic ketamine | “Racemic ketamine (rketamine) is cheap and easy to access; however, the effects in patients who have not responded to electroconvulsive therapy have yet to be understood or tested.” PMID 34882570 ↗ Jan 20222“Metabolomic signatures of intravenous racemic ketamine associated remission in treatment-resistant depression: A pilot hypothesis generating study.” PMID 35738038 ↗ May 2022 “Patients will receive 0.5mg/kg Racemic ketamine IV over 40 min” NCT05019885 ↗ |
| Known as | Racemic Ketamine Hydrochloride | “Low dose ketamine - Ketalar (Racemic Ketamine Hydrochloride) Saline - Isotonic/Normal Saline” NCT04429685 ↗ |
| Known as | rketamine | “Racemic ketamine (rketamine) is cheap and easy to access; however, the effects in patients who have not responded to electroconvulsive therapy have yet to be understood or tested.” PMID 34882570 ↗ Jan 2022 |
| Known as | S (+) Ketamine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00354029 ↗ |
| Known as | S(+)-ketamine hydrochloride | “Patients who undergo general anesthesia using S(+)-ketamine hydrochloride for anesthesia induction, maintenance or postoperative analgesia.” NCT04834427 ↗ |
| Known as | SDK | “sub-dissociative dose ketamine (SDK)” NCT03950817 ↗ |
| Known as | Wafermine | “A Phase 2, Multiple-Dose Study of The Efficacy and Safety of Wafermine™ (Sublingual Ketamine) in Participants Experiencing Acute Post-Operative Bunionectomy or Abdominoplasty Pain” NCT03246971 ↗1“single-dose Wafermine™ (ketamine sublingual wafer)” NCT07691372 ↗ |
| Action | Inhibit | “This study will test whether a single dose of ketamine - a drug that blocks a brain receptor called NMDA - can cause a rapid (next day) antidepressant effect in patients with...” NCT00088699 ↗ |
| Modality | Small molecule | “Kétamine is a derivated of phencyclidine with a sedative, anesthesic, analgesic and amnesiant activity.” NCT01517828 ↗ |
| Route | Intravenous | “administered intravenously (through a vein) over 40 minutes” NCT00088699 ↗ |
| Target | TNF | “Ketamine at low doses, below the normal anesthetic dose, appears to rapidly reduce the production of pro-inflammatory cytokines, especially IL-6 and tumor necrosis factor alpha...” NCT04365985 ↗ |